Pharmalink reports the approval of key patent for chemotherapy drug Busulipo
"This patent extends our robust product protection for Busulipo(tm) to the U.S. and we believe will considerably increase our chances of attracting partnerships aimed at speeding up the commercialisation of Busulipo(tm) in key markets," commented Pharmalink's Managing Director Johan Häggblad.
The reformulation underlying the Busulipo(tm) concept was conceived and developed by Prof. Moustapha Hassan and Dr. Zuzana Hassan at Karolinska Institutet (Sweden). The basis of the Busulipo(tm) concept is a liposome formulation that improves the safety potential, tissue distribution and stability of busulfan. The concept was especially developed for use in children suffering from malignancies or metabolic disorders and in need of bone marrow transplantation. Pharmalink entered an agreement with Prof. Hassan and Dr. Hassan in 2006 aimed at bringing the project to the market. Busulipo(tm) is currently in Phase II clinical trials with more than 90 patients treated.
Pharmalink is currently seeking an industrial partner to support late stage clinical trials and the registration and introduction of Busulipo(tm) into key global markets.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.